Contents

THERAPEUTIC AND DIAGNOSTIC GUIDELINES

706 Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective
Lee LX, Li SC

OPINION REVIEW

721 Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations
Pham PV, Vu NB

REVIEW

731 Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection
Mallis P, Michalopoulos E, Chatzistamatiou T, Stavropoulos-Giokas C

752 Practical choice for robust and efficient differentiation of human pluripotent stem cells
Fang M, Liu LP, Zhou H, Li YM, Zheng YW

761 Human embryonic stem cells as an in vitro model for studying developmental origins of type 2 diabetes
Chen ACH, Lee KF, Yeung WSB, Lee YL

776 Autophagy in fate determination of mesenchymal stem cells and bone remodeling
Chen XD, Tan JL, Feng Y, Huang LJ, Zhang M, Cheng B

787 Stem cell therapy for Alzheimer’s disease
Liu XY, Yang LP, Zhao L

803 Exosomes derived from stem cells as an emerging therapeutic strategy for intervertebral disc degeneration
Hu ZL, Li HY, Chang X, Li YY, Liu CH, Gao XX, Zhai Y, Chen YX, Li CQ

814 Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine
Ma ZJ, Yang JJ, Lu YB, Liu ZY, Wang XX

ORIGINAL ARTICLE

Basic Study

841 Assessment of tobacco heating system 2.4 on osteogenic differentiation of mesenchymal stem cells and primary human osteoblasts compared to conventional cigarettes
Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure
Bahrehbar K, Rezazadeh Valojerdi M, Esfandiari F, Fathi R, Hassani SN, Baharvand H

Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review
Wang JH, Liu XL, Sun JM, Yang JH, Xu DH, Yan SS
ABOUT COVER

Editorial Board member of World Journal of Stem Cells, Dr. Perez-Campo is currently an Associate Professor in the Department of Molecular Biology at the University of Cantabria (Spain). She obtained her degree in Biological Sciences from the University of Salamanca (Spain), where she then went on to complete her PhD in 1999. Dr. Perez-Campo undertook her postdoctoral research at the Paterson Institute for Cancer Research (United Kingdom; currently known as Cancer Research UK Manchester Institute) under the supervision of Prof. Lacaud, where she remained for more than 10 years working in the field of stem cell biology. Upon returning to Spain, she joined the University of Cantabria and focused her research efforts on the molecular mechanisms that control mesenchymal stem cell (MSC) differentiation towards the osteoblastic and adipogenic lineages, and how those mechanisms are altered in osteoporosis. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of World Journal of Stem Cells (WJSC, World J Stem Cells) is to provide scholars and readers from various fields of stem cells with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJSC publishes articles reporting research results obtained in the field of stem cell biology and regenerative medicine, related to the wide range of stem cells including embryonic stem cells, germline stem cells, tissue-specific stem cells, adult stem cells, mesenchymal stromal cells, induced pluripotent stem cells, embryonal carcinoma stem cells, hemangioblasts, lymphoid progenitor cells, etc.

INDEXING/ABSTRACTING

The WJSC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Biological Abstracts, BIOSIS Previews, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJSC as 3.231; IF without journal self cites: 3.128; Ranking: 18 among 29 journals in cell and tissue engineering; Quartile category: Q3; Ranking: 113 among 195 journals in cell biology; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yan-Xia Xing; Production Department Director: Yun-Xiaojian Wu; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Stem Cells

ISSN

ISSN 1948-0210 (online)

LAUNCH DATE

December 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Carlo Ventura

EDITORIAL BOARD MEMBERS


PUBLICATION DATE

August 26, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

E-mail: bpgoffice@wjgnet.com; https://www.wjgnet.com

INSTRUCTIONS TO AUTHORS

https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS

https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS

https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT

https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS

https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION

https://www.f6publishing.com
Autophagy in fate determination of mesenchymal stem cells and bone remodeling

Xiao-Dan Chen, Jia-Li Tan, Yi Feng, Li-Jia Huang, Mei Zhang, Bin Cheng

ORCID number: Xiao-Dan Chen 0000-0003-2510-348X; Jia-Li Tan 0000-0001-8176-8318; Yi Feng 0000-0002-8691-3446; Li-Jia Huang 0000-0003-2818-940X; Mei Zhang 0000-0001-8514-0034; Bin Cheng 0000-0001-7288-806X.

Author contributions: Chen XD was involved in the conceptualization, funding acquisition, and writing of the original draft; Tan JL took part in the conceptualization, funding acquisition, and review and editing of the manuscript; Feng Y, Huang LJ, and Zhang M participated in the provision of resources, and review and editing of the manuscript; Cheng B took part in the conceptualization and funding acquisition, and participated in the supervision, and writing, review, and editing of the manuscript; all authors have read and approved the final manuscript.

Supported by National Natural Science Foundation of China, No. 81873710 and No. 81900976; Guangzhou Foundation for Science and Technology Planning Project, China, No. 201704030083 and No. 201704020063; and Guangdong Financial Fund for High-Caliber Hospital Construction, No. 174-2018-XMZC-0001-03-0125/C-05.

Conflict-of-interest statement: The authors declare no conflict of interest.

Core tip: Autophagy is a dynamic recycling mechanism that fuels cellular renovation and homeostasis. Recent studies have shed light on an essential role of autophagy in orchestrating self-renewal and the multilineage differentiation potential of mesenchymal stem cells.

Abstract
Mesenchymal stem cells (MSCs) have been widely exploited as promising candidates in clinical settings for bone repair and regeneration in view of their self-renewal capacity and multipotentiality. However, little is known about the mechanisms underlying their fate determination, which would illustrate their effectiveness in regenerative medicine. Recent evidence has shed light on a fundamental biological role of autophagy in the maintenance of the regenerative capability of MSCs and bone homeostasis. Autophagy has been implicated in provoking an immediately available cytoprotective mechanism in MSCs against stress, while dysfunction of autophagy impairs the function of MSCs, leading to imbalances of bone remodeling and a wide range of aging and degenerative bone diseases. This review aims to summarize the up-to-date knowledge about the effects of autophagy on MSC fate determination and its role as a stress adaptation response. Meanwhile, we highlight autophagy as a dynamic process and a double-edged sword to account for some discrepancies in the current research. We also discuss the contribution of autophagy to the regulation of bone cells and bone remodeling and emphasize its potential involvement in bone disease.

Key words: Mesenchymal stem cells; Autophagy; Cell self-renewal; Cell differentiation; Cytoprotection; Bone remodeling

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
stem cells (MSCs), thus coordinating bone homeostasis. This review outlines the effects of autophagy on MSCs fate determination and cytoprotection under different kinds of stresses. Moreover, we emphasize that the involvement of autophagy ensures balanced bone remodeling, which will be of significance in facilitating its application as a therapeutic target in bone repair and regeneration.

**Citation:** Chen XD, Tan JL, Feng Y, Huang LJ, Zhang M, Cheng B. Autophagy in fate determination of mesenchymal stem cells and bone remodeling. *World J Stem Cells* 2020; 12(8): 776-786


**DOI:** https://dx.doi.org/10.4252/wjsc.v12.i8.776

**INTRODUCTION**

Mesenchymal stem cells (MSCs) are a heterogeneous cellular population that can be detected in and isolated from bone marrow, adipose, vascular, umbilical cord, placenta, skin, and kidney[13-19]. Characterized by their potential of self-renewal and differentiation into osteogenic, chondrogenic, and adipogenic lineages, they are considered promising therapeutic agents that confer a positive benefit to bone maintenance, repair, and regeneration[18]. Therefore, a thorough understanding of the underlying mechanisms regulating MSCs function would offer great promise in the field of bone regenerative medicine.

Autophagy is a conserved degradation process during which proteins and damaged organelles are engulfed by autophagosomes and then fused with lysosomes to be degraded for intracellular recycling to fuel cellular renovation[20]. There are three types of autophagy in mammals, including macroautophagy[10], microautophagy[21], and chaperone-mediated autophagy[22], among which macroautophagy is in the spotlight for its crucial effects on cell biology and will be henceforth referred to as “autophagy” in this review.

Recent evidence has shed light on a fundamental role of autophagy in the fate determination of MSCs and the maintenance of bone homeostasis. In addition, autophagy has also been implicated as an immediately available cytoprotective mechanism in MSCs against stress[23,24]. Dysfunction of autophagy would impair the function of MSCs, leading to imbalances of bone remodeling and thus inducing a wide range of aging and degenerative bone diseases. Further delineation of the relationships among autophagy, MSCs function, and bone homeostasis would uncover new avenues for novel therapeutic strategies for bone repair and regeneration.

**REGULATORY MECHANISMS OF AUTOPHAGY**

Autophagy is regulated by a number of signaling pathways, among which the most well-known are the adenosine monophosphate-activated protein kinase (AMPK) and the phosphoinositide3 kinase (PI3K)/Akt pathways, which converge on mammalian target of rapamycin (mTOR), a well-recognized negative regulator of autophagy that integrates nutrient signals[12] (Figure 1). mTOR recruits other regulatory proteins to form two distinct complexes, mTORC1 and mTORC2, and mTORC1 is involved in autophagy regulation[25].

AMPK is a principal intracellular energy sensor, which conserves energy by inhibiting mTOR[23] by phosphorylating and potentiating tuberous sclerosis complex (TSC) or by directly binding to RAPTOR, a key subunit of mTORC1[26], and consequently inducing autophagy[27]. Furthermore, the PI3K/Akt pathway is also an important mTOR modulator that inhibits the mTOR repressor TSC[28], activates mTOR, and then blocks autophagy activity[29]. In addition, Wnt/β-catenin has been shown to be a negative regulator of autophagy, while PTEN induces autophagy by inhibiting the PI3K/Akt/mTOR pathway, and activated EGFR/Ras/MEK/ERK, JUK/c-Jun, and p38 MAPK signaling pathways have also been revealed as stimulators of autophagy[30].
Autophagy and the lineage determination of MSCs

Considerable evidence has shown a pivotal regulatory role of autophagy in self-renewal capacity and lineage determination of MSCs. Induction of autophagy in bone mesenchymal stem cells (BMSCs) may account for a decrease in their S-phase population and trigger their differentiation into neurons\(^{19}\). Despite some controversy, Isomoto et al\(^{20}\) clarified that rapamycin does not have a spontaneous osteogenic effect on MSCs, while most studies have confirmed that autophagy contributes to the switch between osteogenesis and adipogenesis of BMSCs. More specifically, MSCs tend to accumulate undergraded autophagic vacuoles and undergo little autophagic turnover, while osteogenic differentiation of MSCs results in more autophagic turnover\(^{21}\). Induction of osteogenic differentiation of human gingiva-derived MSCs (HGMSCs) potentiates autophagy signaling, while inhibition of autophagy precludes osteoblast differentiation of HGMSCs\(^{22}\). The autophagy inducer rapamycin promotes osteoblast differentiation in human embryonic stem cells (ESC) by interfering with mTOR while augmenting the BMP/Smad signaling pathway\(^{23}\).

Osterix-expressing cells with a specific deletion of TSC1, a positive regulator of autophagy, have shown that TSC1 deficiency is responsible for the reduction of bone mass, as characterized by inhibition of osteogenesis, enhancement of osteoclastogenesis, and elevation of bone marrow adiposity\(^{24}\). Consistently, TSC1 deficiency in BMSCs results in decreased proliferation and a tendency to differentiate into adipocytes instead of osteoblasts\(^{24}\).

Other studies have provided evidence that early mTOR suppression accompanied by late Akt/mTOR activation contributes to osteoblast differentiation of MSCs\(^{25}\). Accordingly, activation of autophagy by mTOR inhibition facilitates osteoblast differentiation\(^{25}\), though whether late mTOR induction and subsequent autophagy inhibition would stimulate or interfere with osteogenesis remains to be elucidated. Another study in MC3T3 cells also revealed that early activation and subsequent inhibition of AMPK are indispensable for osteoblast differentiation\(^{26}\). Given that mTOR functions as an inhibitor and AMPK as a stimulator of autophagy, these two studies coincide in that autophagy is fueled at first and then abrogated during osteoblast differentiation. We theorized that such time-dependent catabolic dynamics seem fundamental to ensure the ever-changing energy demands during all stages of osteogenesis.

Autophagy in aging/senescence of MSCs

Although several studies have revealed that autophagy is activated during aging in cells such as fibroblasts\(^{27}\) and BMSCs\(^{28}\), the mainstream view currently is that with aging, autophagy decreases in different kinds of tissues, ranging from the kidney to
the brain\textsuperscript{35-38}. Indeed, it has been reported that autophagy activity is significantly reduced in aged BMSCs compared with their counterparts\textsuperscript{31}. Basal autophagy has a crucial role in the maintenance of the young state of satellite cells, and dysfunction of autophagy leads to cell senescence as indicated by the decrease in satellite cell number and function\textsuperscript{35}. In addition, blockage of autophagy converts young BMSCs to a relatively aged state by impairing their osteoblast differentiation and proliferation potential while promoting their adipocyte differentiation ability. Correspondingly, activation of autophagy turns aged BMSCs into a young state by strengthening osteoblast differentiation and proliferation potential while impairing adipocyte differentiation capacity\textsuperscript{36}. Likewise, pretreatment with rapamycin remarkably alleviates MSC aging induced by D-gal and decreases of p-JNK, p-38, and ROS generation, supporting the concept that autophagy exerts a protective role in MSCs senescence\textsuperscript{29}. This protective effect of rapamycin on MSCs senescence can be abolished by increasing the ROS level, and inhibition of p38 can rescue the H$_2$O$_2$-induced MSCs senescence, which suggests that ROS/JNK/p38 signaling contributes to mediating autophagy-delayed MSCs senescence\textsuperscript{39}.

Collectively, autophagy is a surveillance pathway that tightly controls fate decisions of MSCs, and therefore it should be considered when searching for methods to maintain the pluripotency of MSCs.

### CYTOPROTECTION OF AUTOPHAGY IN MSCS UNDER STRESS

#### Hypoxic conditions

Autophagy is known to exert cytoprotective effects for MSCs under stress conditions\textsuperscript{40}. It has been demonstrated that hypoxia-pretreated MSCs exhibit AMPK/mTOR signaling activation, autophagy enhancement, and pro-angiogenic effect improvements\textsuperscript{41}. Similarly, Zhang \textit{et al.}\textsuperscript{42} showed that the autophagy inhibitor 3-methyladenine (3-MA) promotes hypoxia-induced apoptosis, while a positive inducer of autophagy, rapamycin, decreases hypoxia-induced apoptosis, suggesting that autophagy seems to be a protective element in MSCs under hypoxic stress and that atorvastatin could improve BMSCs survival during hypoxia by enhancing autophagy via the AMPK/mTOR pathway. However, there are also studies showing that hypoxia activates the autophagic flux of BMSCs through the AMPK/mTOR pathway and that activation of the latter process plays an important role in hypoxia-induced apoptosis\textsuperscript{42-49}. This complicated scenario might be due to the heterogeneity and site-specific properties of the MSCs. For instance, BMSCs derived from the mandible have higher expression of the stemness markers Nanog, Oct-4, and Sox2, as well as stronger autophagy and anti-aging capacities under normoxia or hypoxia, when compared to those derived from the tibia\textsuperscript{40}.

#### Oxidative stress

A recent study showed that oxidative stress-induced MSCs death could be prevented by carbon monoxide, and this protective effect is due to an increase of autophagy\textsuperscript{41}. Autophagy facilitates the turnover of damaged cellular components, which may result in improved cellular survival in the setting of oxidative injury. Therefore, depletion of autophagy in MSCs exacerbates oxidative stress-induced MSCs death\textsuperscript{43}. Augmenting autophagy by JNK activation also protects MSCs against oxidative damage, thereby improving MSCs survival\textsuperscript{44}. Preconditioning or coconditioning with rapamycin alleviates, while 3-MA aggravates, H$_2$O$_2$-induced cell apoptosis\textsuperscript{44}. Likewise, H$_2$O$_2$-treated human MSCs (hMSCs) activates FOXO3 and then induces autophagy in response to the elevated ROS level, thus preventing oxidative injury. In line with this, suppression of autophagy impairs ROS elimination and the osteogenic capacity of hMSCs\textsuperscript{45}. However, it is worth noting that these cytoprotective effects of autophagy on MSCs in the context of oxidative damage seem to act in a stress severity- and duration-dependent manner. Autophagy flux is considered to be a self-defensive process during the early stage of MSCs injury induced by H$_2$O$_2$, and this protective effect would be abolished after sustained oxidative exposure (\textit{i.e.}, 6 h), as demonstrated by increased levels of caspase-3 and caspase-6\textsuperscript{46}, which indicates that adaptive autophagy contributes to an improved survival rate of MSCs under stress, while destructive autophagy is induced when it fails to manage excessive stress\textsuperscript{40}.

#### Irradiation stress

As the main mechanism by which cells initiate self-protection in a radiation microenvironment\textsuperscript{40,46}, autophagy triggers a DNA damage response by regulating
DNA repair and checkpoint protein levels\(^5\). Some studies have reported that autophagy decreases after irradiation, suggesting an impairment in eliminating damaged cellular components\(^6\). Activation of autophagy in MSCs reduces radiation-generated ROS and DNA damage, leading to the maintenance of stemness and differentiation potential\(^6,3**, while suppression of autophagy results in more ROS generation, DNA damage, and worsening of self-renewal ability\(^9\). This radio-protective role of autophagy on MSCs is further supported by the observation that hypoxia increases both the autophagy level and MSCs radioresistance via ERK1/2 and mTOR signaling\(^5\), suggesting a positive relationship between autophagy and the radioresistance of MSCs.

**Inflammatory stress**

Increasing evidence has shown that autophagy provides a crucial line of induction and modulation of the inflammatory status of MSCs. In a TNF-α/cycloheximide-induced inflammatory environment, enhancement of autophagy reverses the decreased survival rate of MSCs, while inhibition of autophagy aggravates apoptotic progression\(^9\). Nevertheless, there have been reports of the adverse regulatory effects of autophagy in MSCs. The inflammatory cytokines TNF-α and IFN-γ synergistically enhance autophagy in MSCs, as evidenced by increased expression of BECN1-1/Beclin-1. Knockdown of Becl1 improves the therapeutic effects of MSCS and increases their survival by promoting Bcl-2 expression via the ROS/MAPK1/3 pathway\(^5\). Wang et al.\(^5\) showed that autophagy is triggered in MSCs in response to a liver fibrosis (LF) microenvironment. Of note, autophagy suppression can improve the antifibrotic potential of MSCs and this contributes to their inhibitory effects on T lymphocyte infiltration as well as the production of inflammatory cytokines TNF-α and IFN-γ\(^9\). Additionally, inhibition of autophagy increases ROS accumulation and MAPK 1/3 activation in MSCs, which are essential for prostaglandin E2 expression to exert an immunoregulatory function, thus resulting in enhanced suppression upon activation and expansion of CD4+ T cells and leading to upregulation of the immunosuppressive function of MSCs\(^\)\(\)\(\)\(\)\(\)\(\)\(\). This implies that autophagy may not always be beneficial in protecting the reparative effect of MSCs. Hence, modulating the multifaceted effects of autophagy in MSCs would provide a novel strategy to improve MSCs-based therapy.

**AUTOPHagy AND Bone remodeling**

Bone remodeling is dynamic process that helps to maintain bone integrity and mineral homeostasis. There are three kinds of cell types involved in bone remodeling: Osteoclasts, osteoblasts, and osteocytes\(^\)\(\)\(\)\(\). Among them, both osteoblasts and osteocytes are derived from BMSCs, while osteoclasts have a hematopoietic origin\(^9\). Osteoclasts are multinucleated cells that initiate bone remodeling by digesting old bone, whereas osteoblasts are responsible for synthesizing and secreting bone matrix to form new bone\(^9\). Osteocytes, as the most abundant cell type in bone tissue, are pivotal in bone remodeling by coupling osteoblasts and osteoclasts activities\(^9\) via the receptor activator of NF-kappa B (RANK)/receptor activator of NF-kappa B ligand (RANKL)/osteoprotegerin (OPG) system\(^9\). Though still in its infancy, growing evidence has clarified that autophagy is closely related to bone remodeling mediated by osteoclasts, osteoblasts, and osteocytes, by which it exerts a critical role in coupling bone formation and bone resorption, thus maintaining normal postnatal bone homeostasis\(^9\).

**Autophagy in osteoclasts**

Previous research has demonstrated that activation of autophagy by AMPK signaling inhibits osteoclast differentiation\(^9\). Moreover, autophagy induced by OPG attenuates osteoclast bone resorption via the AKT/mTOR/ULK1 axis\(^9\). Similarly, autophagy favors OPG-mediated inhibition of osteoclast differentiation and bone resorption through the AMPK/mTOR/p70S6K signaling pathway\(^9\). These data highlight a negative regulation of autophagy in osteoclastogenesis. However, Cao et al.\(^9\) showed that inhibiting autophagy suppresses TRPV4-induced osteoclast differentiation and osteoporosis via the Ca²⁺-calcinertin-NFATc1 pathway. In addition, JNK1-induced autophagy decreases apoptosis of osteoclast progenitors and stimulates RANKL-mediated osteoclastogenesis\(^9\), which shows a positive effect of autophagy on osteoclast activity, suggesting a potential role of autophagy in initiating bone remodeling.
**Autophagy in osteoblasts**

Moreover, autophagy promoted by estradiol protects osteoblasts from apoptosis via the ER-ERK-mTOR axis\(^{66}\). Interestingly, both early proliferation and differentiation are not interfered by inactivation of autophagy by *FIP200* ablation, a fundamental element of mammalian autophagy, while osteoblast terminal differentiation is adversely affected, as shown by defective nodule formation\(^ {66}\), which suggests a positive role of autophagy in nodule formation. Consistently, osteoblastic mineralization is found to be accompanied by activation of autophagy, in which vacuoles could act as vehicles for crystals secretion. Thus, osteoblast specific autophagy deficient mice exhibit a significant reduction of mineralization and bone mass\(^ {66}\). Bone mass in osteoblast-specific *Atg7* conditional knockout (cKO) mice is significantly decreased compared with the control, the phenotype of which is caused by a decrease of osteoblast number and mineralization, as well as an increase of osteoclast number and osteoclast activity\(^ {66}\). These results mean that autophagy exerts a critical role in osteoblast differentiation.

**Autophagy in osteocytes**

Yang *et al*\(^ {66}\) suggested a negative correlation between osteocyte autophagy and an ovariectomy (OVX) induced oxidative stress condition and bone loss. Reduction of autophagy by estrogen deficiency promotes the apoptosis of osteocytes, whereas restoration of autophagy strengthens the anti-apoptotic effects to improve osteocyte viability\(^ {66}\). Osteocytes-specific cKO of *Atg7*, a key gene involved in autophagy, results in reduced bone mass, decreased cancellous and cortical bone thickness, and increased cortical bone porosity at 6 mo for both male and female mice, which contributes to decreases in osteoblast number, bone formation rate, and osteoclast number\(^ {66}\). In addition, EphrinB2 in osteocytes limits autophagy to ensure bone quality by controlling mineral accumulation, while dysfunction of the osteocytic EphrinB2-autophagy signal results in bone fragility\(^ {66}\). These findings emphasize a central role of autophagy in regulating osteocyte biology as well as bone remodeling.

**AUTOGRAPHY AND BONE DISEASE**

Increasing numbers of studies have revealed a crucial role of autophagy in the development and progression of many kinds of bone disease, such as osteopetrosis, Paget’s disease, and osteoporosis\(^ {72-78}\). Recently, a genome-wide association study of wrist bone mineral density caught our attention since it revealed a close relationship between osteoporosis and autophagy\(^ {78}\). Further research demonstrated that MSCs from an osteoporosis mouse model induced by estrogen deficiency exhibit reduced autophagy, which is associated with abnormal regenerative function\(^ {78}\). Interestingly, restoration of autophagy by administrating rapamycin rescues the regenerative function of MSCs and protects OVX mice from osteoporotic development\(^ {78}\). A similar decreased level of autophagy is also observed in OVX rats, while restoration of autophagy in osteoblasts by overexpressing autophagy gene damage-regulated autophagy modulator (DRAM) inhibits osteoblast proliferation and promotes their apoptosis\(^ {77}\). In addition, activation of autophagy restored bone loss in aged mice\(^ {61}\), whereas blockade of autophagy alleviated glucocorticoid-induced and OVX-induced bone loss by interfering with osteoclastogenesis\(^ {78}\). What’s more, defective autophagy in osteoblasts results in mouse osteopenia\(^ {78}\). In experimental models of arthritis, rapamycin treatment can reduce the number of osteoclasts and osteoclast formation, thus inhibiting bone absorption in young rats\(^ {78}\). Furthermore, rapamycin reduces bone resorption in renal transplant patients\(^ {79}\), enhances osteogenic differentiation in a mouse model of osteopenia\(^ {78}\), and ameliorates age-induced bone defects in aged rats\(^ {78}\). Further study is warranted to explore the potential application of autophagy modulators as preventive or therapeutic strategies in bone disease.

**CONCLUSION AND FUTURE PERSPECTIVES**

In general, although the prevailing views currently support the hypothesis that autophagy contributes to the maintenance of MSCs integrity by preserving their self-renewal and osteoblast differentiation potential while inhibiting adipocyte differentiation, thus orchestrating bone homeostasis (Figure 2), some data are still somewhat controversial. To some extent, autophagy is a dynamic process that...
depends on immediate cellular energy demands. Thus, it is necessary to investigate its biological role along a timeline instead of at a single isolated time point. In addition, autophagy may act as a double-edged sword, the effects of which are modified in response to the features, severity, and duration of a specific stress. Furthermore, the latest study emphasizes a critical role of mitochondrial autophagy, or mitophagy, in stem cell fate plasticity and determination\cite{83,84}. Effects of an underlying crosstalk between autophagy and endoplasmic reticulum stress in MSCs and bone biology regulation is also beginning to be uncovered\cite{85}. Further study is needed to lift the veil on the pleiotropy of autophagy, its reciprocal and functional interactions with other organelles, and their role in MSCs functional orchestration and bone biology modulation.

REFERENCES


4 Chanda D, Kumar S, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. *J Cell Biochem* 2010; 111: 249-257 [PMID: 20506559 DOI: 10.1002/jcb.22701]


23 Lee KW, Yook YJ, Son MY, Kim MJ, Koo DB, Han YM, Cho YS. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR/Smad pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 2010; 19: 557-568 [PMID: 20990147]
34 Song C, Song C, Tong F. Autophagy induction is a survival response against oxidative stress in bone marrow-derived mesenchymal stromal cells. Cytotechnology 2014; 16: 1361-1370 [PMID: 24980657 DOI: 10.1007/jcyr.2014.04.009]


50 Sugrue T, Lowndes NF, Ceredig R. Hypoxia enhances the radioresistance of mouse mesenchymal stromal cells. Stem Cells 2014; 32: 2188-2200 [PMID: 24578291 DOI: 10.1002/stem.1683]


